Health Care/Hospital
Kazia Licenses Rights to Paxalisib in Greater China to Simcere, a Leading Chinese Pharmaceutical Company
SYDNEY, March 29, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a licensing agreement with Simcere Pharmaceutical Group Ltd (Simcere) (HKSE: 2096) to develop and commercialise...
2021-03-29 17:43
5681
Discussing Expansion of Travel Corridor Arrangement, Minister of Tourism Holds a Coordination Meeting
BALI, Indonesia, March 29, 2021 /PRNewswire/ -- Minister of Tourism and Creative Economy, Sandiaga Salahuddin Uno, organizes a ministerial coordination meeting regarding the expansion of the travel corridor arrangement for the tourism and creative economy sector, which allows return tourist visit...
2021-03-29 17:06
5759
Johnson & Johnson Announces Advance Purchase Agreement with the African Vaccine Acquisition Trust for the Company's COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., March 29, 2021 /PRNewswire/ -- Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vaccine Acquisition Task Team (AVATT) to make available up to 220 million dos...
2021-03-29 16:07
5969
HOYA Confirm the Long Term Technical Collaboration and Supply Agreement Related to Endoscopic Ultrasound Systems
TOKYO, March 29, 2021 /PRNewswire/ -- HOYA Corporation (TSE:7741, "HOYA") today confirms that the five year contract announced onJuly 6, 2020 for technical collaboration and supply of diagnostics ultrasound systems and ultrasound sensor with Hitachi, will become effective as ofMarch 31st of 2021....
2021-03-29 16:00
3293
Getinge introduces a long-term flexible workplace approach
GOTHENBURG, Sweden, March 29, 2021 /PRNewswire/ -- Three out of four Getinge employees who have worked from home during the COVID-19 pandemic believe that the setup has improved their productivity as well as their work-life harmony. As a result, the company is introducing a long-term flexible wor...
2021-03-29 15:40
3504
Jacobio Pharma Announces CNY486 Million Revenue for 2020 Annual Results
BEIJING and BOSTON, March 29, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) announced its first annual results after itsHong Kong listing. By the end ofDecember 31, 2020, its annual revenue was 486 million yuan and R&D expenses exceeded230 million yuan and increased 66% compared to 2019....
2021-03-29 13:11
3835
Gilead Sciences Announces Launch of Asia Pacific Rainbow Grant 2021
- Grant Program Invites Applications from HIV-Focused Community-Based Organizations in the Asia Pacific Region to Fund Innovation Projects - - To Date, Grant Has Awarded Nearly US $3 Million to Organizations Across Asia Pacific - HONG KONG, March 29, 2021 /PRNewswire/ -- Gilead Sciences, Inc. to...
2021-03-29 11:00
2489
Navigating China's Medical Technology, Regulations, Quality, and Future; Hundreds of Experts Gathered at On-site Conferences of Medtec China
SHANGHAI, March 29, 2021 /PRNewswire/ -- Medtec China 2021 will be held in Halls 2&4 of the Shanghai World Expo Exhibition Hall on September 1–3, and the "Innovation Technology Forum and Regulation Summit" will be held at the same time. This summit caters to the development trend and focus of Ch...
2021-03-29 09:30
3677
Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint
SHANGHAI, March 29, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the Phase 2 study of its innovative PD-1 inhibitor HLX10 in patients with unresectable or metastatic microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) solid tumors that fail t...
2021-03-29 08:27
4944
Making Most out of Launched Products Fueling Diversified Innovation through Integrated Platform
SHANGHAI, March 28, 2021 /PRNewswire/ -- Henlius (2696.HK) announced the financial results for the year ended31 December 2020. 2020 marked a meaningful year for Henlius as the Company gathered the pace in commercialization and continued the momentum for innovation. The Company delivered a total r...
2021-03-28 11:16
3673
Foresee Pharmaceuticals Announces Dosing of First Patient in Phase 2/3 Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS
TAIPEIMarch 27, 2021 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), today announced the initiation of patient dosing in the Phase 2/3 clinical trial of FP-025, its highly selective oral MMP-12 inhibitor, in adult patients with severe to critical COVID-19 with associated...
2021-03-28 11:04
3013
China Pharma Holdings, Inc. Reports Fiscal Year 2020 Financial Results
HAIKOU CITY, China, March 26, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced financial results for the ...
2021-03-27 05:00
9939
FARE Launches Global Research Competition to Develop a Safe & Compassionate Diagnostic Test for Patients with Food Allergies
- $3 Million in Prize Money Inspires the World's Leading Food Allergy Researchers to Put an End to the Oral Food Challenge - Aimmune Therapeutics - Nestlé Health Science Partnership, Financial Support & Global Reach Anchor FAITH Challenge MCLEAN, Va., March 27, 2021 /PRNewswire/ -- FARE, the wor...
2021-03-27 04:25
3420
Genscript Biotech Reports Full Year 2020 Financial Results
Highlights: * Revenue of the Group for the year ended December 31, 2020 was approximately US$390.8 million, representing an increase of 42.9% as compared with approximatelyUS$273.4 million for the year ended December 31, 2019 * Gross profit of the Group for the year ended December 31, 2...
2021-03-27 02:16
7343
Modern Chinese Medicine Announces Year 2020 Annual Results
Solid growth with focus to broaden the distribution network and raise R&D efforts PERFORMANCE HIGHLIGHTS * The Group posted a consolidated revenue of approximately RMB308.7 million for the year ended31 December 2020, representing an increase of approximately 41.1%. * For the year ended 31 D...
2021-03-26 22:08
12493
Saxenda® recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12-17 years
BAGSVÆRD, Denmark, March 26, 2021 /PRNewswire/ -- Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use of Saxenda® is expanded for the treatment of obesity in adolescents aged 12–17 years...
2021-03-26 21:31
4031
Kintor Pharmaceutical Limited Announces 2020 Business Progress and Annual Results
SUZHOU, China, March 26, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (stock code 9939.HK, "Kintor Pharmaceutical" or the "Company"), a clinical-stage biotechnology company developing small molecule and biological therapeutics, recently announced its business highlights and financial result...
2021-03-26 20:54
6919
InnoCare Releases 2020 Annual Results and Business Highlights
BEIJING, March 26, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2020 annual results which ended onDec. 31, 2020. Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, "During 2020...
2021-03-26 19:39
6194
Artificial Joint Surgical Robot, CUVIS-joint developed by CUREXO Receives EEA CE Marking
* Expands partnership with European implant and medical enterprises * Pursues US FDA approval SEOUL, South Korea, March 26, 2021 /PRNewswire/ -- On the 25th, medical robot company CUREXO, Inc. (KOSDAQ: 060280) announced that the in-house developed artificial joint surgical robot CUVIS-joint re...
2021-03-26 17:00
3671
Airway Therapeutics Announces FDA Acceptance of IND for AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)
Initiating Phase 1b randomized clinical trial with initial results expected in late 2021 Potential for novel, preventive AT-100 to reduce incidence and severity of serious respiratory disease BPD, improving outcomes and survival in very preterm infants CINCINNATI, March 26, 2021 /PRNewswire/ --...
2021-03-26 16:00
3483
Week's Top Stories
Most Reposted
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 278 media titles]
2025-12-26 12:55ACEN completes transition to 100% renewable energy
[Picked up by 273 media titles]
2025-12-29 18:53Vietnam's Newest EDM Destination, APLUS SAIGON, Debuts With Star-Studded Soft Opening Weekends Featuring Dombresky and Argy
[Picked up by 273 media titles]
2025-12-30 20:12
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
[Picked up by 271 media titles]
2026-01-01 10:00
CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 263 media titles]
2025-12-29 09:00
